Multinational Lung Cancer Control Program (MLCCP)

Multinational Lung Cancer Control Programme (MLCCP) aims to enhance public access to early diagnostic services, treatment, and care for lung cancer. This multi-million rand project – is new in the African continent, running in the following 6 countries: Kenya / South Africa / Tanzania / Ethiopia / Lesotho / Eswatini In South Africa, the project has four key functions (1) to raise awareness about lung cancer in KwaZulu-Natal, (2) to provide an access "gate" for lung cancer patients to receive primitive treatment through conducting a needs-based assessment (3) to diagnose, refer and provide treatment to affected persons who have lung cancer risk symptoms (4) evaluate factors that determine the progressive utilization of palliative care services by patients with cancer in the public and private sectors. The program is currently funded by the Bristol-Myers Squibb Foundation (BMSF). The MLCCP project is now in phase 2. This phase was launched in April 2019 and is currently recruiting. This phase of the project includes the clinical component, building on the foundations laid by the first phase by adding a clinical component evaluating lung health, histological subtypes, and genetics of lung cancer, clinic The al presentation, treatment outcomes, and pulmonary rehabilitation. The project is currently based at two sites which are Addington hospital where an MLCCP diagnostic unit has been set up, the second site is in Inkosi Albert Luthuli Central Hospital (IALCH) where other lung cancer patients come as referrals from peripheral base hospitals. Two more sites are to be included and to be actively recruiting, which are Grey's hospital and Ngwelezane hospital”